1. Home
  2. CPHC vs BMEA Comparison

CPHC vs BMEA Comparison

Compare CPHC & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Canterbury Park Holding Corporation 'New'

CPHC

Canterbury Park Holding Corporation 'New'

N/A

Current Price

$16.84

Market Cap

81.1M

ML Signal

N/A

Logo Biomea Fusion Inc.

BMEA

Biomea Fusion Inc.

HOLD

Current Price

$1.32

Market Cap

85.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CPHC
BMEA
Founded
1994
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Services-Misc. Amusement & Recreation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
81.1M
85.3M
IPO Year
2016
2021

Fundamental Metrics

Financial Performance
Metric
CPHC
BMEA
Price
$16.84
$1.32
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$9.83
AVG Volume (30 Days)
1.6K
918.6K
Earning Date
05-07-2026
05-12-2026
Dividend Yield
1.79%
N/A
EPS Growth
N/A
69.19
EPS
0.03
N/A
Revenue
$59,227,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$523.00
N/A
Revenue Growth
0.14
N/A
52 Week Low
$14.49
$0.87
52 Week High
$21.61
$2.99

Technical Indicators

Market Signals
Indicator
CPHC
BMEA
Relative Strength Index (RSI) 56.03 51.91
Support Level $16.03 $1.23
Resistance Level $17.42 $1.46
Average True Range (ATR) 0.24 0.08
MACD 0.01 0.02
Stochastic Oscillator 74.99 91.26

Price Performance

Historical Comparison
CPHC
BMEA

About CPHC Canterbury Park Holding Corporation 'New'

Canterbury Park Holding Corp is in the business of pari-mutuel wagering on horse races and unbanked card games at its canterbury park racetrack and card casino facility in Minnesota. The company has four operating segments. The horse racing segment represents pari-mutuel wagering operations on simulcast and lives horse races; the Casino segment represents unbanked card operations; the food and beverage segment includes concessions, catering, and events services provided at the Racetrack; and the real estate development segment represents its real estate development operations. The firm generates a majority of its revenue from the Casino segment.

About BMEA Biomea Fusion Inc.

Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.

Share on Social Networks: